We assessed the effects of the HA synthesis inhibitor 4‐methylumbelliferone (4‐MU) on SPHK1 expression in ovarian cancer cells and HGSOC patient tissues using ex vivo tissue explant assays. The gene discussed is SPHK1; the disease is ovarian cancer.